Pain Management Market Report Key Highlights

• Global pain management market revenue is poised to garner USD 83,348 Million by 2030 with a CAGR of 6.5% from 2022 to 2030
• North America dominated the maximum market with over 40% shares in 2021
• According to CDC, chronic pain affected more than 100 million Americans in 2018
• Asia-Pacific pain management market is poised to grow with a significant CAGR from 2022 to 2030
• Based on application segment, neuropathic pain gathered more than 30% of the total market share in 2021
• Surging number of sport injuries propels the pain management market value

Gradual increase in number of patients suffering from chronic cancer and diabetes, coupled with high government spending on hospital infrastructure in order to provide enhanced care are major factors expected to drive the growth of global market. According to U.S. Department of Health & Human Services in 2016, an estimated 20.4% of U.S. adults (50.0 million) had chronic pain and 8.0% of U.S. adults (19.6 million) had high-impact chronic pain.

Global Pain Management Market Dynamics

Market Drivers

• Growing incidences of chronic pain
• Rising prevalence of sport injuries
• Increasing number of surgical procedures
• Huge base of elderly population

Market Restraints

• High purchase and procedural cost of pain management devices
• Availability of other therapies

Market Opportunities

• Rapid advancements in drug development
• Expanding base of pain management clinics and centers throughout the world

Pain Managements Market Report Coverage

Pain Management Market Insights

Favorable business policies and emergence of small and mid-size enterprises with advanced solutions are factors expected to support the growth of target market. In addition, players focus on tracking the untapped market in developing countries is expected to support the growth of target market.

However, factors such as high cost of devices and stringent government regulations related to product approval are expected to hamper the growth of global pain management market. In addition, lack of advanced infrastructure in developing countries for adoption of advanced devices is expected to challenge the growth of target market.

Rapid technological advancements by major players, integration of AI in devices coupled with introduction of innovative solutions are factors responsible to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership and agreements between regional and international players is expected to support the revenue growth of target market

Pain Management Market Segmentation

The worldwide pain management market is split based on mode of pain management, application, and geography.

Pain Management Market By Mode Of Pain Management

• Drugs
  • Opioids
  • Non-Narcotic Analgesics
    • NSAIDS
    • Anesthetics
    • Anticonvulsants
    • Anti-Depressants
    • Other Non-Narcotic Analgesics
• Devices
  • Neurostimulation Devices
    • Transcutaneous Electrical Nerve Stimulation (TENS) Devices
    • Brain and Spinal Cord Stimulation (SCS) Devices
  • Analgesic Infusion Pumps
    • Intrathecal Infusion Pumps
    • External Infusion Pumps

According to our pain management industry analysis, the drugs accounted for a considerable market share in 2021. Among al the dugs, opioids category was the largest contributor to the market in 2021 because of opioids' great efficiency in relieving pain in major chronic illnesses. During the projection period, the anaesthetics segment is expected to increase at the fastest rate. Among all the devices, neurostimulation devices dominated the market with significant pain management market share.

Pain Management Market By Application

• Neuropathic Pain
• Cancer Pain
• Facial Pain and Migraine
• Musculoskeletal Pain
• Other Applications

Acccodting to pain management market forecast, the neuropathic pain application occupied a noteworthy market share from 2022 to 2030. The presence of a big patient population is a crucial factor driving up demand for pharmaceuticals in the market. Neuropathic pain affects between 3% and 17% of persons. Furthermore, cancer pain and chronic back pain are predicted to expand at the fastest rates during the forecast period, owing to an increase in the number of operations worldwide and an increase in the incidence of chronic diseases that cause back pain.

Pain Management Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa

According to CDC over 65% of the US elderly population suffers from chronic pain

The North America pain management market is expected to account for significant revenue share owing to availability of enhanced pain care management, increasing number of patients suffering from chronic diseases, availability of favorable insurance policies, and growing base of aging population. With an increase in the older population, the market is predicted to grow at a faster rate, as the ageing population is more susceptible to chronic illness. Presence of large number of players operating in the country and approach towards introduction of innovative solutions are factors expected to boost the growth of target market. During the projection period, the Asia-Pacific pain management market is expected to develop at the fastest rate. This expansion can be attributed to R&D efforts in the development of technologically advanced healthcare treatment solutions.

Pain Management Market Players

Some of the top pain management companies offered in the professional report include Abbott Laboratories, AstraZeneca PLC, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Johnson & Johnson, Medtronic PLC, Novartis International AG, and Pfizer Inc.

Increasing investment by major players for R&D activities, and approach towards introduction of smart devices are factors responsible for the growth of target market. In addition, strategic merger and acquisition activities by major players in order to enhance the business presence are factors expected to augment the growth of target market.

In 2019, NeuroPace, Inc. launched Senza® Omnia™ Spinal Cord Stimulation System in the US for the treatment of chronic pain. This is expected to help the company to enhance the product portfolio and enhance the profit ratio.

In 2018, Abbott a multinational medical devices and health care company signed an agreement with National Institutes of Health (NIH), US in order to provide neuromodulation technologies, including directional DBS, SCS, and DRG therapy, for NIH research and further explore the applications.

In 2019, Boston Scientific Corp. engages launched Spectra WaveWriter™ Spinal Cord Stimulator System for treatment of chronic pain and simultaneously combine paresthesia-based and sub-perception therapy in Europe. This is expected to help the company to strengthen its position in Europe.

In 2018, NeuroPace a global operating company that designs, develops, manufactures and market implantable devices for the treatment of neurological disorders launched RNS system for treatment of refractory epilepsy. This is expected to help the company to enhance the customer base.